Intravitreal Topotecan for Proliferative Vitreoretinopathy

This study focuses on testing a new way to treat a condition called Proliferative Vitreoretinopathy (PVR), which can happen after a specific kind of retinal detachment known as rhegmatogenous retinal detachment (RRD). In PVR, unwanted cell growth occurs on and around the retina, which can lead to surgical failures when trying to fix the retinal detachment. Current treatments for PVR, like corticosteroids and 5-fluorouracil, do not work consistently well, so there is no standard treatment. The study is exploring the use of a drug called Topotecan, which has shown potential in treating similar eye conditions, to see if it can effectively and safely manage PVR. Participants in the study will receive Topotecan directly into the eye through an injection, a method known as intravitreal injection. This approach has been previously used for other eye conditions without causing major side effects. Researchers will carefully monitor the participants to evaluate the drug's effectiveness in reducing the unwanted cell growth associated with PVR and to ensure it does not cause any harm. The study aims to gather data on both the safety and potential benefits of using Topotecan to treat PVR, which could help in developing a more reliable treatment option for those affected by this condition.